[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Urea Cycle Disorders Treatment Drug Supply, Demand and Key Producers, 2023-2029

May 2023 | 114 pages | ID: GCF0FD26D73AEN
GlobalInfoResearch

US$ 4,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Urea Cycle Disorders Treatment Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Urea Cycle Disorders Treatment Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Urea Cycle Disorders Treatment Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Urea Cycle Disorders Treatment Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Urea Cycle Disorders Treatment Drug total market, 2018-2029, (USD Million)

Global Urea Cycle Disorders Treatment Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Urea Cycle Disorders Treatment Drug total market, key domestic companies and share, (USD Million)

Global Urea Cycle Disorders Treatment Drug revenue by player and market share 2018-2023, (USD Million)

Global Urea Cycle Disorders Treatment Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global Urea Cycle Disorders Treatment Drug total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Urea Cycle Disorders Treatment Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc., Recordati Rare Diseases Inc., Nestle S.A., Danone S.A., Lucane Pharma SA, Acer Therapeutics Inc., Ultragenyx Pharmaceutical and Aeglea Biotherapeutics, Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Urea Cycle Disorders Treatment Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Urea Cycle Disorders Treatment Drug Market, By Region:
  • United States
  • China
  • Europe
  • Japan
  • South Korea
  • ASEAN
  • India
  • Rest of World
Global Urea Cycle Disorders Treatment Drug Market, Segmentation by Type
  • Amino Acid Supplements
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate
  • Others
Global Urea Cycle Disorders Treatment Drug Market, Segmentation by Application
  • Hospital
  • Clinic
  • Others
Companies Profiled:
  • Horizon Therapeutics Plc
  • Bausch Health Companies Inc.
  • Recordati Rare Diseases Inc.
  • Nestle S.A.
  • Danone S.A.
  • Lucane Pharma SA
  • Acer Therapeutics Inc.
  • Ultragenyx Pharmaceutical
  • Aeglea Biotherapeutics, Inc
  • Arcturus Therapeutics Holdings Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc.
  • Abbott
  • Mead Johnson & Company, LLC
Key Questions Answered

1. How big is the global Urea Cycle Disorders Treatment Drug market?

2. What is the demand of the global Urea Cycle Disorders Treatment Drug market?

3. What is the year over year growth of the global Urea Cycle Disorders Treatment Drug market?

4. What is the total value of the global Urea Cycle Disorders Treatment Drug market?

5. Who are the major players in the global Urea Cycle Disorders Treatment Drug market?

6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY

1.1 Urea Cycle Disorders Treatment Drug Introduction
1.2 World Urea Cycle Disorders Treatment Drug Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Urea Cycle Disorders Treatment Drug Total Market by Region (by Headquarter Location)
  1.3.1 World Urea Cycle Disorders Treatment Drug Market Size by Region (2018-2029), (by Headquarter Location)
  1.3.2 United States Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.3 China Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.4 Europe Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.5 Japan Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.6 South Korea Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.7 ASEAN Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
  1.3.8 India Urea Cycle Disorders Treatment Drug Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Urea Cycle Disorders Treatment Drug Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Urea Cycle Disorders Treatment Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

2.1 World Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.2 World Urea Cycle Disorders Treatment Drug Consumption Value by Region
  2.2.1 World Urea Cycle Disorders Treatment Drug Consumption Value by Region (2018-2023)
  2.2.2 World Urea Cycle Disorders Treatment Drug Consumption Value Forecast by Region (2024-2029)
2.3 United States Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.4 China Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.5 Europe Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.6 Japan Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.7 South Korea Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.8 ASEAN Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)
2.9 India Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029)

3 WORLD UREA CYCLE DISORDERS TREATMENT DRUG COMPANIES COMPETITIVE ANALYSIS

3.1 World Urea Cycle Disorders Treatment Drug Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Urea Cycle Disorders Treatment Drug Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Urea Cycle Disorders Treatment Drug in 2022
  3.2.3 Global Concentration Ratios (CR8) for Urea Cycle Disorders Treatment Drug in 2022
3.3 Urea Cycle Disorders Treatment Drug Company Evaluation Quadrant
3.4 Urea Cycle Disorders Treatment Drug Market: Overall Company Footprint Analysis
  3.4.1 Urea Cycle Disorders Treatment Drug Market: Region Footprint
  3.4.2 Urea Cycle Disorders Treatment Drug Market: Company Product Type Footprint
  3.4.3 Urea Cycle Disorders Treatment Drug Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Urea Cycle Disorders Treatment Drug Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Urea Cycle Disorders Treatment Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  4.1.2 United States VS China: Urea Cycle Disorders Treatment Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Urea Cycle Disorders Treatment Drug Consumption Value Comparison
  4.2.1 United States VS China: Urea Cycle Disorders Treatment Drug Consumption Value Comparison (2018 & 2022 & 2029)
  4.2.2 United States VS China: Urea Cycle Disorders Treatment Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Urea Cycle Disorders Treatment Drug Companies and Market Share, 2018-2023
  4.3.1 United States Based Urea Cycle Disorders Treatment Drug Companies, Headquarters (States, Country)
  4.3.2 United States Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023)
4.4 China Based Companies Urea Cycle Disorders Treatment Drug Revenue and Market Share, 2018-2023
  4.4.1 China Based Urea Cycle Disorders Treatment Drug Companies, Company Headquarters (Province, Country)
  4.4.2 China Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023)
4.5 Rest of World Based Urea Cycle Disorders Treatment Drug Companies and Market Share, 2018-2023
  4.5.1 Rest of World Based Urea Cycle Disorders Treatment Drug Companies, Headquarters (States, Country)
  4.5.2 Rest of World Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Urea Cycle Disorders Treatment Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
  5.2.1 Amino Acid Supplements
  5.2.2 Sodium Phenylbutyrate
  5.2.3 Glycerol Phenylbutyrate
  5.2.4 Sodium Benzoate
  5.2.5 Others
5.3 Market Segment by Type
  5.3.1 World Urea Cycle Disorders Treatment Drug Market Size by Type (2018-2023)
  5.3.2 World Urea Cycle Disorders Treatment Drug Market Size by Type (2024-2029)
  5.3.3 World Urea Cycle Disorders Treatment Drug Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Urea Cycle Disorders Treatment Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
  6.2.1 Hospital
  6.2.2 Clinic
  6.2.3 Others
6.3 Market Segment by Application
  6.3.1 World Urea Cycle Disorders Treatment Drug Market Size by Application (2018-2023)
  6.3.2 World Urea Cycle Disorders Treatment Drug Market Size by Application (2024-2029)
  6.3.3 World Urea Cycle Disorders Treatment Drug Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Horizon Therapeutics Plc
  7.1.1 Horizon Therapeutics Plc Details
  7.1.2 Horizon Therapeutics Plc Major Business
  7.1.3 Horizon Therapeutics Plc Urea Cycle Disorders Treatment Drug Product and Services
  7.1.4 Horizon Therapeutics Plc Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.1.5 Horizon Therapeutics Plc Recent Developments/Updates
  7.1.6 Horizon Therapeutics Plc Competitive Strengths & Weaknesses
7.2 Bausch Health Companies Inc.
  7.2.1 Bausch Health Companies Inc. Details
  7.2.2 Bausch Health Companies Inc. Major Business
  7.2.3 Bausch Health Companies Inc. Urea Cycle Disorders Treatment Drug Product and Services
  7.2.4 Bausch Health Companies Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.2.5 Bausch Health Companies Inc. Recent Developments/Updates
  7.2.6 Bausch Health Companies Inc. Competitive Strengths & Weaknesses
7.3 Recordati Rare Diseases Inc.
  7.3.1 Recordati Rare Diseases Inc. Details
  7.3.2 Recordati Rare Diseases Inc. Major Business
  7.3.3 Recordati Rare Diseases Inc. Urea Cycle Disorders Treatment Drug Product and Services
  7.3.4 Recordati Rare Diseases Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.3.5 Recordati Rare Diseases Inc. Recent Developments/Updates
  7.3.6 Recordati Rare Diseases Inc. Competitive Strengths & Weaknesses
7.4 Nestle S.A.
  7.4.1 Nestle S.A. Details
  7.4.2 Nestle S.A. Major Business
  7.4.3 Nestle S.A. Urea Cycle Disorders Treatment Drug Product and Services
  7.4.4 Nestle S.A. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.4.5 Nestle S.A. Recent Developments/Updates
  7.4.6 Nestle S.A. Competitive Strengths & Weaknesses
7.5 Danone S.A.
  7.5.1 Danone S.A. Details
  7.5.2 Danone S.A. Major Business
  7.5.3 Danone S.A. Urea Cycle Disorders Treatment Drug Product and Services
  7.5.4 Danone S.A. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.5.5 Danone S.A. Recent Developments/Updates
  7.5.6 Danone S.A. Competitive Strengths & Weaknesses
7.6 Lucane Pharma SA
  7.6.1 Lucane Pharma SA Details
  7.6.2 Lucane Pharma SA Major Business
  7.6.3 Lucane Pharma SA Urea Cycle Disorders Treatment Drug Product and Services
  7.6.4 Lucane Pharma SA Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.6.5 Lucane Pharma SA Recent Developments/Updates
  7.6.6 Lucane Pharma SA Competitive Strengths & Weaknesses
7.7 Acer Therapeutics Inc.
  7.7.1 Acer Therapeutics Inc. Details
  7.7.2 Acer Therapeutics Inc. Major Business
  7.7.3 Acer Therapeutics Inc. Urea Cycle Disorders Treatment Drug Product and Services
  7.7.4 Acer Therapeutics Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.7.5 Acer Therapeutics Inc. Recent Developments/Updates
  7.7.6 Acer Therapeutics Inc. Competitive Strengths & Weaknesses
7.8 Ultragenyx Pharmaceutical
  7.8.1 Ultragenyx Pharmaceutical Details
  7.8.2 Ultragenyx Pharmaceutical Major Business
  7.8.3 Ultragenyx Pharmaceutical Urea Cycle Disorders Treatment Drug Product and Services
  7.8.4 Ultragenyx Pharmaceutical Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.8.5 Ultragenyx Pharmaceutical Recent Developments/Updates
  7.8.6 Ultragenyx Pharmaceutical Competitive Strengths & Weaknesses
7.9 Aeglea Biotherapeutics, Inc
  7.9.1 Aeglea Biotherapeutics, Inc Details
  7.9.2 Aeglea Biotherapeutics, Inc Major Business
  7.9.3 Aeglea Biotherapeutics, Inc Urea Cycle Disorders Treatment Drug Product and Services
  7.9.4 Aeglea Biotherapeutics, Inc Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.9.5 Aeglea Biotherapeutics, Inc Recent Developments/Updates
  7.9.6 Aeglea Biotherapeutics, Inc Competitive Strengths & Weaknesses
7.10 Arcturus Therapeutics Holdings Inc.
  7.10.1 Arcturus Therapeutics Holdings Inc. Details
  7.10.2 Arcturus Therapeutics Holdings Inc. Major Business
  7.10.3 Arcturus Therapeutics Holdings Inc. Urea Cycle Disorders Treatment Drug Product and Services
  7.10.4 Arcturus Therapeutics Holdings Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.10.5 Arcturus Therapeutics Holdings Inc. Recent Developments/Updates
  7.10.6 Arcturus Therapeutics Holdings Inc. Competitive Strengths & Weaknesses
7.11 Orpharma Pty Ltd.
  7.11.1 Orpharma Pty Ltd. Details
  7.11.2 Orpharma Pty Ltd. Major Business
  7.11.3 Orpharma Pty Ltd. Urea Cycle Disorders Treatment Drug Product and Services
  7.11.4 Orpharma Pty Ltd. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.11.5 Orpharma Pty Ltd. Recent Developments/Updates
  7.11.6 Orpharma Pty Ltd. Competitive Strengths & Weaknesses
7.12 Selecta Biosciences, Inc.
  7.12.1 Selecta Biosciences, Inc. Details
  7.12.2 Selecta Biosciences, Inc. Major Business
  7.12.3 Selecta Biosciences, Inc. Urea Cycle Disorders Treatment Drug Product and Services
  7.12.4 Selecta Biosciences, Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.12.5 Selecta Biosciences, Inc. Recent Developments/Updates
  7.12.6 Selecta Biosciences, Inc. Competitive Strengths & Weaknesses
7.13 Abbott
  7.13.1 Abbott Details
  7.13.2 Abbott Major Business
  7.13.3 Abbott Urea Cycle Disorders Treatment Drug Product and Services
  7.13.4 Abbott Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.13.5 Abbott Recent Developments/Updates
  7.13.6 Abbott Competitive Strengths & Weaknesses
7.14 Mead Johnson & Company, LLC
  7.14.1 Mead Johnson & Company, LLC Details
  7.14.2 Mead Johnson & Company, LLC Major Business
  7.14.3 Mead Johnson & Company, LLC Urea Cycle Disorders Treatment Drug Product and Services
  7.14.4 Mead Johnson & Company, LLC Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
  7.14.5 Mead Johnson & Company, LLC Recent Developments/Updates
  7.14.6 Mead Johnson & Company, LLC Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Urea Cycle Disorders Treatment Drug Industry Chain
8.2 Urea Cycle Disorders Treatment Drug Upstream Analysis
8.3 Urea Cycle Disorders Treatment Drug Midstream Analysis
8.4 Urea Cycle Disorders Treatment Drug Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

LIST OF TABLES

Table 1. World Urea Cycle Disorders Treatment Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Urea Cycle Disorders Treatment Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Urea Cycle Disorders Treatment Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Urea Cycle Disorders Treatment Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Urea Cycle Disorders Treatment Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Urea Cycle Disorders Treatment Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Urea Cycle Disorders Treatment Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Urea Cycle Disorders Treatment Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Urea Cycle Disorders Treatment Drug Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Urea Cycle Disorders Treatment Drug Players in 2022
Table 12. World Urea Cycle Disorders Treatment Drug Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Urea Cycle Disorders Treatment Drug Company Evaluation Quadrant
Table 14. Head Office of Key Urea Cycle Disorders Treatment Drug Player
Table 15. Urea Cycle Disorders Treatment Drug Market: Company Product Type Footprint
Table 16. Urea Cycle Disorders Treatment Drug Market: Company Product Application Footprint
Table 17. Urea Cycle Disorders Treatment Drug Mergers & Acquisitions Activity
Table 18. United States VS China Urea Cycle Disorders Treatment Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Urea Cycle Disorders Treatment Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Urea Cycle Disorders Treatment Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Urea Cycle Disorders Treatment Drug Revenue Market Share (2018-2023)
Table 23. China Based Urea Cycle Disorders Treatment Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Urea Cycle Disorders Treatment Drug Revenue Market Share (2018-2023)
Table 26. Rest of World Based Urea Cycle Disorders Treatment Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Urea Cycle Disorders Treatment Drug Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Urea Cycle Disorders Treatment Drug Revenue Market Share (2018-2023)
Table 29. World Urea Cycle Disorders Treatment Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Urea Cycle Disorders Treatment Drug Market Size by Type (2018-2023) & (USD Million)
Table 31. World Urea Cycle Disorders Treatment Drug Market Size by Type (2024-2029) & (USD Million)
Table 32. World Urea Cycle Disorders Treatment Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Urea Cycle Disorders Treatment Drug Market Size by Application (2018-2023) & (USD Million)
Table 34. World Urea Cycle Disorders Treatment Drug Market Size by Application (2024-2029) & (USD Million)
Table 35. Horizon Therapeutics Plc Basic Information, Area Served and Competitors
Table 36. Horizon Therapeutics Plc Major Business
Table 37. Horizon Therapeutics Plc Urea Cycle Disorders Treatment Drug Product and Services
Table 38. Horizon Therapeutics Plc Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Horizon Therapeutics Plc Recent Developments/Updates
Table 40. Horizon Therapeutics Plc Competitive Strengths & Weaknesses
Table 41. Bausch Health Companies Inc. Basic Information, Area Served and Competitors
Table 42. Bausch Health Companies Inc. Major Business
Table 43. Bausch Health Companies Inc. Urea Cycle Disorders Treatment Drug Product and Services
Table 44. Bausch Health Companies Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Bausch Health Companies Inc. Recent Developments/Updates
Table 46. Bausch Health Companies Inc. Competitive Strengths & Weaknesses
Table 47. Recordati Rare Diseases Inc. Basic Information, Area Served and Competitors
Table 48. Recordati Rare Diseases Inc. Major Business
Table 49. Recordati Rare Diseases Inc. Urea Cycle Disorders Treatment Drug Product and Services
Table 50. Recordati Rare Diseases Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Recordati Rare Diseases Inc. Recent Developments/Updates
Table 52. Recordati Rare Diseases Inc. Competitive Strengths & Weaknesses
Table 53. Nestle S.A. Basic Information, Area Served and Competitors
Table 54. Nestle S.A. Major Business
Table 55. Nestle S.A. Urea Cycle Disorders Treatment Drug Product and Services
Table 56. Nestle S.A. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Nestle S.A. Recent Developments/Updates
Table 58. Nestle S.A. Competitive Strengths & Weaknesses
Table 59. Danone S.A. Basic Information, Area Served and Competitors
Table 60. Danone S.A. Major Business
Table 61. Danone S.A. Urea Cycle Disorders Treatment Drug Product and Services
Table 62. Danone S.A. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Danone S.A. Recent Developments/Updates
Table 64. Danone S.A. Competitive Strengths & Weaknesses
Table 65. Lucane Pharma SA Basic Information, Area Served and Competitors
Table 66. Lucane Pharma SA Major Business
Table 67. Lucane Pharma SA Urea Cycle Disorders Treatment Drug Product and Services
Table 68. Lucane Pharma SA Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lucane Pharma SA Recent Developments/Updates
Table 70. Lucane Pharma SA Competitive Strengths & Weaknesses
Table 71. Acer Therapeutics Inc. Basic Information, Area Served and Competitors
Table 72. Acer Therapeutics Inc. Major Business
Table 73. Acer Therapeutics Inc. Urea Cycle Disorders Treatment Drug Product and Services
Table 74. Acer Therapeutics Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Acer Therapeutics Inc. Recent Developments/Updates
Table 76. Acer Therapeutics Inc. Competitive Strengths & Weaknesses
Table 77. Ultragenyx Pharmaceutical Basic Information, Area Served and Competitors
Table 78. Ultragenyx Pharmaceutical Major Business
Table 79. Ultragenyx Pharmaceutical Urea Cycle Disorders Treatment Drug Product and Services
Table 80. Ultragenyx Pharmaceutical Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Ultragenyx Pharmaceutical Recent Developments/Updates
Table 82. Ultragenyx Pharmaceutical Competitive Strengths & Weaknesses
Table 83. Aeglea Biotherapeutics, Inc Basic Information, Area Served and Competitors
Table 84. Aeglea Biotherapeutics, Inc Major Business
Table 85. Aeglea Biotherapeutics, Inc Urea Cycle Disorders Treatment Drug Product and Services
Table 86. Aeglea Biotherapeutics, Inc Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Aeglea Biotherapeutics, Inc Recent Developments/Updates
Table 88. Aeglea Biotherapeutics, Inc Competitive Strengths & Weaknesses
Table 89. Arcturus Therapeutics Holdings Inc. Basic Information, Area Served and Competitors
Table 90. Arcturus Therapeutics Holdings Inc. Major Business
Table 91. Arcturus Therapeutics Holdings Inc. Urea Cycle Disorders Treatment Drug Product and Services
Table 92. Arcturus Therapeutics Holdings Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Arcturus Therapeutics Holdings Inc. Recent Developments/Updates
Table 94. Arcturus Therapeutics Holdings Inc. Competitive Strengths & Weaknesses
Table 95. Orpharma Pty Ltd. Basic Information, Area Served and Competitors
Table 96. Orpharma Pty Ltd. Major Business
Table 97. Orpharma Pty Ltd. Urea Cycle Disorders Treatment Drug Product and Services
Table 98. Orpharma Pty Ltd. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Orpharma Pty Ltd. Recent Developments/Updates
Table 100. Orpharma Pty Ltd. Competitive Strengths & Weaknesses
Table 101. Selecta Biosciences, Inc. Basic Information, Area Served and Competitors
Table 102. Selecta Biosciences, Inc. Major Business
Table 103. Selecta Biosciences, Inc. Urea Cycle Disorders Treatment Drug Product and Services
Table 104. Selecta Biosciences, Inc. Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Selecta Biosciences, Inc. Recent Developments/Updates
Table 106. Selecta Biosciences, Inc. Competitive Strengths & Weaknesses
Table 107. Abbott Basic Information, Area Served and Competitors
Table 108. Abbott Major Business
Table 109. Abbott Urea Cycle Disorders Treatment Drug Product and Services
Table 110. Abbott Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Abbott Recent Developments/Updates
Table 112. Mead Johnson & Company, LLC Basic Information, Area Served and Competitors
Table 113. Mead Johnson & Company, LLC Major Business
Table 114. Mead Johnson & Company, LLC Urea Cycle Disorders Treatment Drug Product and Services
Table 115. Mead Johnson & Company, LLC Urea Cycle Disorders Treatment Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 116. Global Key Players of Urea Cycle Disorders Treatment Drug Upstream (Raw Materials)
Table 117. Urea Cycle Disorders Treatment Drug Typical Customers

LIST OF FIGURES

Figure 1. Urea Cycle Disorders Treatment Drug Picture
Figure 2. World Urea Cycle Disorders Treatment Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Urea Cycle Disorders Treatment Drug Total Market Size (2018-2029) & (USD Million)
Figure 4. World Urea Cycle Disorders Treatment Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Urea Cycle Disorders Treatment Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Urea Cycle Disorders Treatment Drug Revenue (2018-2029) & (USD Million)
Figure 13. Urea Cycle Disorders Treatment Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 16. World Urea Cycle Disorders Treatment Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 18. China Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. India Urea Cycle Disorders Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Urea Cycle Disorders Treatment Drug by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Urea Cycle Disorders Treatment Drug Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Urea Cycle Disorders Treatment Drug Markets in 2022
Figure 27. United States VS China: Urea Cycle Disorders Treatment Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Urea Cycle Disorders Treatment Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Urea Cycle Disorders Treatment Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Urea Cycle Disorders Treatment Drug Market Size Market Share by Type in 2022
Figure 31. Amino Acid Supplements
Figure 32. Sodium Phenylbutyrate
Figure 33. Glycerol Phenylbutyrate
Figure 34. Sodium Benzoate
Figure 35. Others
Figure 36. World Urea Cycle Disorders Treatment Drug Market Size Market Share by Type (2018-2029)
Figure 37. World Urea Cycle Disorders Treatment Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 38. World Urea Cycle Disorders Treatment Drug Market Size Market Share by Application in 2022
Figure 39. Hospital
Figure 40. Clinic
Figure 41. Others
Figure 42. Urea Cycle Disorders Treatment Drug Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source


More Publications